For quite a more detail on this issue, see /zika.
2016 January: Walter Reed Army Institute of Research (WRAIR) begins development of a vaccine candidate for Zika virus, based on its work in developing vaccines “against other flaviviruses, such as yellow fever, dengue and Japanese encephalitis.”
Today, KEI received a letter from the U.S. Army dated April 21, 2017, signed by Barry M. Datlof, in which the Army largely rejected concerns raised in comments submitted by KEI and various other public interest groups related to the proposed grant of an exclusive license to the French drug company Sanofi on a U.S. Army-invented vaccine for Zika virus.
Continue Reading
On March 21, 2017, the New York Times published a letter signed by Dr. Elias Zerhouni, defending the proposed Sanofi monopoly on the US Army patents to the Zika virus. The letter is available from the NYT from the following link, and also reprinted here, followed by commentary.
https://www.nytimes.com/2017/03/21/opinion/developing-a-zika-vaccine.html
To the Editor:
Re “Trump Should Avoid a Bad Zika Deal” (Op-Ed, March 11):
On March 10, 2017, KEI filed our 3rd set of comments with the U.S. Army Medical Research and Material Command (USAMRMC) on their proposed grant of an exclusive license on Zika virus vaccine patents to the French pharmaceutical company Sanofi.
May 19, 2017: Groups appeal Army decision
Timeline of U.S. Army & Sanofi Zika Vaccine Collaboration
April 21, 2017. U.S. Army Response to Comments on license
Sanofi’s recent fines for fraud, kickbacks, etc: /sanofi-fines
KNOWLEDGE ECOLOGY INTERNATIONAL
FOR IMMEDIATE RELEASE
12 JANUARY 2017
CONTACT: Zack Struver, zack.struver@keionline.org, +1 (202) 332-2670
Groups Object to Army Proposal to Give Sanofi a Monopoly on Patents for Taxpayer-Funded Zika Vaccine
December 21, 2016 — KEI has filed comments with the U.S. Army Medical Research and Materiel Command (USAMRMC) on the proposed grant of an exclusive license to Sanofi on patents on a vaccine for Zika Virus.
DHHS has declared a public health emergency over the Zika virus, and authorized emergency use of diagnostic tests. (Copy here)
The National Institute of Standards and Technology (NIST) issued a Request for Information on December 8, 2023 regarding the “Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights” (88 FR 85593). The request follows a nearly year-long interagency… Continue Reading
On March 31, 2020, KEI received a copy of the contract between Johnson & Johnson (“J&J”) and the Department of Health and Human Services (HHS) for the development of J&J’s COVID-19 vaccine.The contract, which is now valued at $1.3 billion,… Continue Reading